Lenalidomide Plus Melphalan Without Prednisone for Previously Untreated Older Patients With Multiple Myeloma: A Phase II Trial

Micro-Abstract The Myeloma.11 study evaluated the tolerability and efficacy of melphalan plus lenalidomide in patients with untreated multiple myeloma. Four dose levels were tested, including a final dose level of melphalan 5 mg/m2 days 1 to 4 and lenalidomide 10 mg/d days 1 to 21 every 28 days in a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2013-02, Vol.13 (1), p.19-24
Hauptverfasser:	White, Darrell J, Bahlis, Nizar J, Marcellus, Deb C, Belch, Andrew, Stewart, A. Keith, Chen, Christine, Kovacs, Michael J, Macdonald, David A, Reece, Donna E, Reiman, Tony, Harnett, Erica, Meyer, Ralph M, Chapman, Judy-Anne W, Couban, Stephen
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Combined Modality Therapy Corticosteroids Female Hematology, Oncology and Palliative Medicine Humans Lenalidomide Male Melphalan Melphalan - administration & dosage Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - pathology Multiple Myeloma - surgery Neoplasm Staging Phase II trial Prednisone - administration & dosage Stem Cell Transplantation - methods Thalidomide - administration & dosage Thalidomide - analogs & derivatives Transplantation, Autologous
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Micro-Abstract The Myeloma.11 study evaluated the tolerability and efficacy of melphalan plus lenalidomide in patients with untreated multiple myeloma. Four dose levels were tested, including a final dose level of melphalan 5 mg/m2 days 1 to 4 and lenalidomide 10 mg/d days 1 to 21 every 28 days in a single-arm phase II trial. A total of 50 patients were treated with results that demonstrated excess toxicity at all dosing levels tested.
ISSN:	2152-2650 2152-2669
DOI:	10.1016/j.clml.2012.08.009